Medherant has been shortlisted for the CPhI Pharma Awards in both the Formulation and Drug Delivery Devices categories for its TEPI Patch® technology. This year marks the 15th anniversary of the CPhI Pharma Awards which are among the most prestigious awards in the Pharmaceutical industry. The awards recognise innovative and ground-breaking companies.
The TEPI Patch technology enables the development of drug-in-adhesive patch products with better adhesion and enables more efficient drug delivery through the skin. TEPI patches also have a high loading capacity and can be used with a wider variety of drugs than alternative platforms - overcoming many of the existing problems associated with transdermal drug delivery and opening up many new product opportunities. TEPI Patch technology utilises a novel adhesive which provides a better patient experience by sticking to the skin for longer, it is waterproof, is less painful to remove, and does not leave a mark on the skin after removal. Find out more about Medherant’s drug delivery patches here.
Good luck to all the other finalists, the winners will be announced at the CPhI Awards gala on the evening of 9th of October. Dr Andrew Lee, Medherant’s Director of Commercial development, will be attending the event.